Tom Steyer Remains Bullish on Revolution Medicines (RVMD)

Revolution Medicines Inc. (NASDAQ:RVMD) has seen increased ownership by Farallon Capital, holding over 14 million shares as of Q4 2025. The company recently reported statistically significant results from its Phase 3 RASolute 302 trial for daraxonrasib in metastatic pancreatic cancer and is preparing to present full data at the ASCO Plenary Session in May.

By Usman Kabir May 2, 2026 2 min read · Yahoo Finance · May 2, 2026, 14:51 UTC

Tom Steyer Remains Bullish on Revolution Medicines (RVMD)

Tickers: $RVMD

Topics: hedge fund activity pharmaceutical development stock performance

Read the full article at Yahoo Finance

More World news

Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC
LexisNexis Report Shows Elevated U.S. Auto Insurance Shopping Volumes in Q3 2026 PR Newswire · November 12, 2026, 17:12 UTC
Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC